579 related articles for article (PubMed ID: 16338209)
21. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
[TBL] [Abstract][Full Text] [Related]
22. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
Okura Y; Miyakoshi A; Kohyama K; Park IK; Staufenbiel M; Matsumoto Y
Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9619-24. PubMed ID: 16769900
[TBL] [Abstract][Full Text] [Related]
23. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Schenk D
Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
[No Abstract] [Full Text] [Related]
24. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
Boche D; Denham N; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
[TBL] [Abstract][Full Text] [Related]
25. Antibody-mediated immunotherapy for Alzheimer's disease.
Solomon B
Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
[TBL] [Abstract][Full Text] [Related]
26. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
[TBL] [Abstract][Full Text] [Related]
27. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for Alzheimer's disease.
Steinitz M
Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
[TBL] [Abstract][Full Text] [Related]
29. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
[TBL] [Abstract][Full Text] [Related]
30. Anti-Abeta: The good, the bad, and the unforeseen.
Broytman O; Malter JS
J Neurosci Res; 2004 Feb; 75(3):301-6. PubMed ID: 14743443
[TBL] [Abstract][Full Text] [Related]
31. [Novel vaccine therapy for Alzheimer's disease--recent progress and our approach].
Okura Y; Matsumoto Y
Brain Nerve; 2008 Aug; 60(8):931-40. PubMed ID: 18717197
[TBL] [Abstract][Full Text] [Related]
32. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine.
Li SB; Wang HQ; Lin X; Xu J; Xie Y; Yuan QF; Yao ZB
Chin Med J (Engl); 2005 Apr; 118(8):660-4. PubMed ID: 15899121
[TBL] [Abstract][Full Text] [Related]
33. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
[TBL] [Abstract][Full Text] [Related]
34. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.
Wang YJ; Pollard A; Zhong JH; Dong XY; Wu XB; Zhou HD; Zhou XF
Neurobiol Aging; 2009 Mar; 30(3):364-76. PubMed ID: 17686552
[TBL] [Abstract][Full Text] [Related]
35. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
36. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis.
Lee EB; Leng LZ; Lee VM; Trojanowski JQ
FEBS Lett; 2005 May; 579(12):2564-8. PubMed ID: 15862291
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.
Bach P; Tschäpe JA; Kopietz F; Braun G; Baade JK; Wiederhold KH; Staufenbiel M; Prinz M; Deller T; Kalinke U; Buchholz CJ; Müller UC
J Immunol; 2009 Jun; 182(12):7613-24. PubMed ID: 19494285
[TBL] [Abstract][Full Text] [Related]
38. Lessons from the AN 1792 Alzheimer vaccine: lest we forget.
Robinson SR; Bishop GM; Lee HG; Münch G
Neurobiol Aging; 2004; 25(5):609-15. PubMed ID: 15172738
[TBL] [Abstract][Full Text] [Related]
39. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.
DeMattos RB; Bales KR; Cummins DJ; Paul SM; Holtzman DM
Science; 2002 Mar; 295(5563):2264-7. PubMed ID: 11910111
[TBL] [Abstract][Full Text] [Related]
40. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.
Seubert P; Barbour R; Khan K; Motter R; Tang P; Kholodenko D; Kling K; Schenk D; Johnson-Wood K; Schroeter S; Gill D; Jacobsen JS; Pangalos M; Basi G; Games D
Neurodegener Dis; 2008; 5(2):65-71. PubMed ID: 18182780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
